Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/103360
Author(s): | Carlos Santos Tiago Neto Pedro Ferreirinha Hugo Sousa Joana Ribeiro Margarida M. S. M. Bastos Ana I. Faustino Rocha Paula A. Oliveira Rui Medeiros Manuel Vilanova Gil da Costa, R. M. |
Title: | Celecoxib promotes degranulation of CD8(+) T cells in HPV-induced lesions of K14-HPV16 transgenic mice |
Issue Date: | 2016-07-15 |
Abstract: | Aims: Human papillomavirus (HPV) is a known biologic carcinogen which is commonly transmitted through sexual intercourse. CD8(+) T cells are known effectors against tumour cells and an important prognostic marker in HPV-induced cancers. COX-2 inhibitors enhance CD8(+) T cell activity against some cancers. In this work, we sought to study the presence and activation of CD8(+) T lymphocytes in lesions from K14-HPV16 transgenic mice and the immunomodulatory effect of celecoxib (CXB) over these cells. Main methods: Skin samples of CXB-treated and untreated HPV16(-/-) and HPV16(+/-) mice were enzymatically digested and analysed by flow cytometry to assess CD8+ and CD8(+) CD107a(+) T cell infiltrates. Matched skin samples were classified histologically. Key findings: HPV16(+/-) mice presented higher CD8(+) T cell infiltration than HPV16(-/-) animals (P < 0.001). Older HPV16(+/-) animals showed epidermal dysplasia and increased percentages of CD8+ CD107a(+) T cells compared with younger animals with hyperplasia (P < 0.001), validating this model for testing the effects of celecoxib on CD8(+) T cells. CXB-treated HPV16(+/-) mice showed higher percentages of CD8(+) CD107a(+) T cells compared with untreated HPV16(+/-) animals (P < 0.01), but no differences were observed concerning the progression of epidermal lesions. Significance: These findings indicate that celecoxib enhances the degranulation of CD8(+) T cells on HPV16-induced lesions, suggesting the potential clinical use of COX-2 inhibitors. Additionally, this study demonstrates the usefulness of the K14-HPV16 mouse model for testing therapeutic immunomodulatory approaches. |
URI: | https://hdl.handle.net/10216/103360 |
Related Information: | info:eu-repo/grantAgreement/FCT - Fundação para a Ciência e a Tecnologia/Projetos Estratégicos/UID/EQU/00511/2013 - POCI-01-0145-FEDER-006939/Laboratório de Engenharia de Processos, Ambiente, Biotecnologia e Energia/LEPABE |
Document Type: | Artigo em Revista Científica Internacional |
Rights: | restrictedAccess |
Appears in Collections: | FEUP - Artigo em Revista Científica Internacional ICBAS - Artigo em Revista Científica Internacional |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
153301.pdf Restricted Access | Artigo original publicado | 1.13 MB | Adobe PDF | Request a copy from the Author(s) |
153301.1.pdf | Post-Print version | 1.51 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.